RELiZORB

DEVICE3 trials

Sponsors

Alcresta Therapeutics, Inc., Boston Children's Hospital, Massachusetts General Hospital

Conditions

Exocrine Pancreatic InsufficiencyExocrine Pancreatic Insufficiency (EPI)MalabsorptionPancreatitisShort Bowel Syndrome

Phase 3

Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

RecruitingNCT06691893

Massachusetts General HospitalExocrine Pancreatic Insufficiency (EPI), Pancreatitis

Start: 2025-03-28End: 2027-07-15Target: 60Updated: 2026-05-15

Unknown Phase

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

CompletedNCT02598128

Alcresta Therapeutics, Inc.Exocrine Pancreatic Insufficiency

Start: 2015-11-30End: 2016-06-30Updated: 2017-01-25

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

RecruitingNCT03530852

Boston Children's HospitalMalabsorption, Short Bowel Syndrome

Start: 2018-11-21End: 2028-09-30Target: 32Updated: 2026-08-03

Related Papers

Fat digestion using RELiZORB in children with short bowel syndrome who are dependent on parenteral nutrition: Protocol for a 90-day, phase 3, open labeled study

PLoS ONE2023-03-017 citations